CN103298456A - Glp-1颗粒和组合物 - Google Patents

Glp-1颗粒和组合物 Download PDF

Info

Publication number
CN103298456A
CN103298456A CN2012800058571A CN201280005857A CN103298456A CN 103298456 A CN103298456 A CN 103298456A CN 2012800058571 A CN2012800058571 A CN 2012800058571A CN 201280005857 A CN201280005857 A CN 201280005857A CN 103298456 A CN103298456 A CN 103298456A
Authority
CN
China
Prior art keywords
glp
ethyoxyl
amino
compound
liraglutide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800058571A
Other languages
English (en)
Chinese (zh)
Inventor
P.巴施米特
J.德鲁斯特鲁普
K.胡尤斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN103298456A publication Critical patent/CN103298456A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN2012800058571A 2011-01-19 2012-01-19 Glp-1颗粒和组合物 Pending CN103298456A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11151456 2011-01-19
EP11151456.8 2011-01-19
US201161436804P 2011-01-27 2011-01-27
US61/436,804 2011-01-27
PCT/EP2012/050785 WO2012098188A1 (en) 2011-01-19 2012-01-19 Glp-1 particles and compositions

Publications (1)

Publication Number Publication Date
CN103298456A true CN103298456A (zh) 2013-09-11

Family

ID=43899633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800058571A Pending CN103298456A (zh) 2011-01-19 2012-01-19 Glp-1颗粒和组合物

Country Status (5)

Country Link
US (1) US20140004198A1 (enExample)
EP (1) EP2665470A1 (enExample)
JP (1) JP2014502985A (enExample)
CN (1) CN103298456A (enExample)
WO (1) WO2012098188A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096330A (zh) * 2020-06-02 2022-02-25 维白奥锤有限公司 金属相变化合物及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104055735B (zh) * 2013-03-22 2016-08-03 深圳翰宇药业股份有限公司 一种萨摩鲁泰的脂质体及其制备方法
CN106132985B (zh) * 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
ES2929218T3 (es) 2015-01-12 2022-11-28 Enteris Biopharma Inc Formas farmacéuticas orales sólidas
WO2017025990A1 (en) * 2015-08-13 2017-02-16 Sun Pharma Advanced Research Company Limited Long acting liraglutide compositions
CN109195622A (zh) * 2016-03-01 2019-01-11 深圳翰宇药业股份有限公司 一种药物组合物及其制备方法
US20190105268A1 (en) * 2016-03-31 2019-04-11 Sun Pharma Advanced Research Company Limited Viscoelastic Gel of Liraglutide Adapted for Once-Weekly or Once Bi-Weekly Administration
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN115484935A (zh) * 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
CN111888334B (zh) * 2020-06-28 2022-03-18 苏州天微肽生物医药科技有限公司 一种利拉鲁肽微球缓释剂及其制备方法和应用
CN115887351B (zh) * 2023-01-03 2023-05-05 中科微针（北京）科技有限公司 一种glp-1受体激动剂类药物微针组合物、由其制备得到的微针及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388053B1 (en) * 1993-12-09 2002-05-14 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CN101646424A (zh) * 2007-03-27 2010-02-10 菲特伦株式会社 用于控释艾赛那肽的组合物和微球及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7531094A (en) * 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
US7101843B2 (en) * 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
CN104000779A (zh) * 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388053B1 (en) * 1993-12-09 2002-05-14 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CN101646424A (zh) * 2007-03-27 2010-02-10 菲特伦株式会社 用于控释艾赛那肽的组合物和微球及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F.TRADING，ET. AL.,: ""BIOLOGICAL AND CHEMICAL PROPERTIES OF TWO GLUCAGON PREPARATIONS WITH PROLONGED ACTION"", < EUROPEAN JOURNAL OF PHARMACOLOGY>, 31 December 1969 (1969-12-31), pages 206 - 210 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096330A (zh) * 2020-06-02 2022-02-25 维白奥锤有限公司 金属相变化合物及其制备方法

Also Published As

Publication number Publication date
JP2014502985A (ja) 2014-02-06
EP2665470A1 (en) 2013-11-27
US20140004198A1 (en) 2014-01-02
WO2012098188A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
CN103298456A (zh) Glp-1颗粒和组合物
EP2877158B1 (en) A liquid formulation of long acting insulinotropic peptide conjugate
US10335489B2 (en) Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
RU2440097C2 (ru) Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
JP5241849B2 (ja) インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
US8993516B2 (en) Meal-time insulin analogues of enhanced stability
KR101772372B1 (ko) Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
US20030069182A1 (en) Protein formulations
JP2002524514A (ja) タンパク質製剤
TW201113032A (en) Slow-acting insulin preparations
TW201105346A (en) Heat-stable and vibration-stable insulin preparations
US20190060410A1 (en) Pharmaceutical Formulation Comprising GLP-1 Analogue and Preparation Method Thereof
CN104010652A (zh) 超浓缩的速效胰岛素类似物制剂
CN103298457A (zh) Glp-1组合物
US20230212227A1 (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
US20220144915A1 (en) Stabilization of prandial or basal insulin analogues by an internal diselenide bridge
AU2013368990B2 (en) Pharmaceutical composition
TW202327643A (zh) 包含類升糖素肽2(glp-2)類似物之組合物之調配方法
Paavola et al. Insulin
TW202500183A (zh) 包括環糊精的醫藥調配物
Anand Controlled release of insulin and modified insulin from a novel injectable biodegradable gel
HK1204565B (en) A liquid formulation of long acting insulinotropic peptide conjugate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130911